Rating Change
Canaccord Genuity reiterated its Buy rating on Tenax Therapeutics, Inc. (NASDAQ:TENX) on August 11, 2026.
reiterateNASDAQ:TENX
Canaccord Genuity Reiterates Buy Rating on Tenax Therapeutics, Inc. (TENX)
Canaccord Genuity reiterated its Buy rating on Tenax Therapeutics, Inc. (NASDAQ:TENX) on August 11, 2026.
At publication ·
What changed
Tenax Therapeutics, Inc. (NASDAQ:TENX) · reiterate
- Firm
- Canaccord Genuity
- Rating
- Buy to Buy
- Price at event
- $1.62
- Market capitalization
- $45.0M
At a glance
Key takeaways
- Canaccord Genuity reiterated a Buy rating on Tenax Therapeutics (TENX) on August 11, 2026, with the stock trading at $1.62 and a market capitalization of $45.0 million.
Market Context
Tenax Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $1.62 with a market capitalization of $45.0M.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tenax Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tenax Therapeutics, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 11, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 11, 2026 | Chardan Capital | Neutral | N/A |
| Aug 11, 2026 | Guggenheim | Buy | N/A |
| Aug 11, 2026 | Evercore ISI Group | In-Line | N/A |
| Aug 10, 2026 | William Blair | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View TENX Stock Page
Frequently Asked Questions
What does the Buy rating mean for TENX?
A rating of Buy from Canaccord Genuity reflects the analyst's outlook on Tenax Therapeutics, Inc. (NASDAQ:TENX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TENX forecast page.